Veda Giri, MD, outlines points of consensus and areas of disagreement across national and international guideline recommendations for germline testing in prostate cancer.

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

Ensuring consistent diagnostic quality remains critical.

The approval is supported by data from the phase 3 MK-3475A-D77 trial.

Among the topics covered are BCG dosing and maintenance regimens.

The Altaviva device is a minimally invasive implantable tibial neuromodulation therapy for patients with urge urinary incontinence.

According to the authors, these findings suggest that FloStent could serve as an effective interim solution for men who are awaiting TURP.

The phase 2 trial has shown encouraging safety and efficacy results for carotuximab and apalutamide in patients with mCRPC.

Both the Dornier Hoover Flexible and Navigable Suction Ureteral Access Sheath and the Dornier Axis II Slim single-use ureteroscope are FDA-cleared.

Jane T. Kurtzman, MD, underscores the collaborative role of urologists and trauma surgeons in addressing this issue.

John P. Sfakianos, MD, discusses the significance of urine-based biomarkers for intermediate-risk patients and outlines key findings from the STRATA study.

A. Lenore Ackerman, MD, PhD, discusses the renewed emphasis on symptom resolution over microbial eradication in the new AUA guideline for recurrent uUTI in women.

According to the authors, these findings suggest that biparametric MRI could become the new standard of care for prostate cancer diagnosis.

Andrew J. Kirsch, MD, FAAP, FACS, outlines current therapies, ranging from behavioral strategies, such as limiting fluids before bedtime, to bedwetting alarms and medications like DDAVP.

Among men without prostate cancer at baseline, healthier dietary patterns appeared somewhat protective.

Apolo emphasized the value of having robust monotherapy data before advancing into combination strategies.

Two-year outcomes from the ASPIRE trial continued to show that the SURE procedure led to significantly reduced health care consumption events compared with ureteroscopy.

The NDA is supported by data from a phase 3 trial, which demonstrated a 75% complete response rate at 3 months.

Data showed a marked or moderate improvement in IC/BPS symptoms in 41% of patients who received sunobinop vs 9% of patients who received placebo.

Data from the SunRISe-1 trial showed a complete response rate of 82%, with 51% of patients remaining in complete response for at least 1 year.

Miles-Thomas emphasized the importance of Northwestern’s thoughtful implementation strategy.

"Based on this proposal, some shifts may significantly impact the practice of urology," write Jonathan Rubenstein, MD, and Mark Painter.

Rana R. McKay, MD, FASCO, highlights notable takeaways from the COMRADE trial, assessing the combination of olaparib plus radium-223 in CRPC.

Kevin Koo, MD, MPH, discusses a recent study on the utility of a digital stone measurement tool for ureteroscopy.

Surprisingly, the Mediterranean diet—which has shown benefits in other areas of health—was not consistently linked to prostate cancer risk reduction.

CG Oncology plans to initiate a BLA submission with the FDA in Q4 of 2025.

The biomarker panel demonstrated the ability to detect prostate cancer even in men with prostate-specific antigen levels in the normal range.

The LEGEND trial is evaluating detalimogene voraplasmid in patients with high-risk non–muscle invasive bladder cancer.

The trial is assessing RFS rates with cretostimogene grenadenorepvec vs surveillance following TURBT.

The report showed rising incidence rates and a slowing of mortality declines in addition to persistent racial disparities.

Predicine has submitted the first module of a PMA application for their urine cfDNA NGS assay PredicineCARE.

Hong Truong, MD, MS, highlights key findings on genetic counseling rates in patients with kidney cancer.

A recap of the FDA submissions and regulatory decisions in urology from August 2025.

Sandip M. Prasad, MD, MPhil, outlines 3 key takeaways from the ENVISION trial, which evaluated mitomycin for intravesical solution in patients with LG-IR-NMIBC.

The new guidelines provide evidence-based recommendations for treating patients with traumatic injuries to the kidneys, bladder, ureters, urethra, and genitalia.

The approval is supported by findings from an open-label, single-arm, phase 3 trial.

Rana R. McKay, MD, FASCO, details the key efficacy and safety findings from the phase 2 COMRADE trial.

The FDA has declined to approve 89Zr-DFO-girentuximab for PET imaging of ccRCC.

Timothy D. McClure, MD, offers his thoughts on how future advancements will inform the role for focal therapy in prostate cancer.

Christopher Weight, MD, MS, discusses the current state and directions of AI and prostate cancer.

Jennifer A. Robles, MD, MPH, discusses the future for HoLEP in terms of innovation and wider integration into urologic practice.

Gvili explains that many patients with pelvic floor dysfunction are young men (20–45 years old), though he also treats patients who have undergone radical prostatectomy.

Darolutamide plus ADT has also been approved in the US as well as in the European Union.

Kevin Shee, MD, PhD, shares findings on factors associated with recurrence and treatment failure following HIFU for prostate cancer.

The approval of oral sulopenem was supported by data from the phase 3 SURE 1 (NCT03366207) and REASSURE (NCT05584657) trials.

First Assist: GU Oncology Unpacked, hosted by Taylor Goodstein, MD, is a multimedia podcast produced by Urology Times focused on genitourinary oncology. This podcast offers guideline updates, expert c...

"We are lucky to be in the position to offer so many treatment options customized to address [patients'] needs and help them enjoy life," says Kevin C. Zorn, MD, FRCSC, FACS.

Timothy D. McClure, MD, outlines key findings from the PRESERVE trial, which evaluated IRE for prostate tissue ablation in patients with intermediate-risk prostate cancer.